EU REACH amendment on endocrine disruptors: implications for chemical suppliers

Background

On 15 July 2026 the European Commission adopted an amendment to the REACH Regulation that expands the list of substances of very high concern (SVHC) to include a broader range of endocrine‑disrupting chemicals (EDCs) European Commission – REACH overview. The change aligns EU policy with the World Health Organisation’s latest scientific assessment and introduces a staggered registration timetable that begins in 2027. While the amendment is a continuation of the EU’s long‑term strategy to eliminate hazardous chemicals, its timing and scope create immediate operational challenges for suppliers that serve both EU and non‑EU markets.

Key provisions of the amendment

The amendment contains three inter‑related elements:

1. Expanded EDC criteria – Substances that show adverse effects on the endocrine system at concentrations below 0.1 µg L⁻¹ in water are now automatically classified as SVHCs, regardless of their current classification under CLP.
2. Phased registration deadlines – Manufacturers and importers of newly listed EDCs must submit a dossier by 31 December 2027 for quantities above 1 tonne per year, with a second deadline of 31 December 2029 for quantities between 0.1 tonne and 1 tonne.
3. Supply‑chain communication obligations – Down‑stream users must receive a clear safety data sheet (SDS) that highlights the EDC status and any risk‑reduction measures. Non‑compliance may trigger a market‑withdrawal notice under Article 95 of REACH.

The amendment also amends Annex XVIII of REACH to require pre‑registration of any substance that is chemically similar to an existing SVHC, a move aimed at curbing “regrettable substitution”.

Immediate impact on suppliers

1. Data gaps and testing costs

Many mid‑size suppliers lack the toxicological data needed to demonstrate that a product does not meet the new EDC thresholds. Generating the required in‑vitro and in‑vivo studies can add €30 000–€80 000 per substance, a cost that is often passed on to downstream customers.

2. Portfolio reassessment

Products containing borderline substances must be re‑evaluated. For example, Hexakis(bromomethyl)benzene, used as a cross‑linker in polymer formulations, is now flagged for review because its brominated aromatic structure is known to exhibit weak estrogenic activity in rodent assays EU‑ECHA database. Suppliers will need to decide whether to invest in additional data, reformulate, or discontinue the product.

3. Contractual and logistical adjustments

Existing supply agreements often reference the REACH Candidate List as of a specific date. The amendment makes those clauses obsolete, requiring renegotiation to include the new EDC list and the pre‑registration requirement. Failure to update contracts can result in non‑compliance penalties of up to €10 million per infringement under Article 100 of REACH.

4. Market access risk

Non‑EU customers increasingly demand EU‑compliant documentation. A supplier that cannot provide an up‑to‑date SDS for an EDC‑listed substance risks losing orders from major pharmaceutical and cosmetics manufacturers that have zero‑tolerance policies for SVHCs.

Practical steps for suppliers

To mitigate disruption, suppliers should adopt a structured approach:

• Conduct a rapid inventory of all substances on hand that match the new EDC criteria. Prioritise those with annual volumes above 0.5 tonne.
• Engage a third‑party data provider to obtain or verify endocrine‑disruption data. Many providers now offer bundled dossiers that satisfy REACH pre‑registration requirements.
• Update SDS templates to include a dedicated “Endocrine‑Disrupting Property” section, referencing the latest CLP classification.
• Review contractual language with downstream users. Insert clauses that allow for amendment of SVHC listings without renegotiating the entire agreement.
• Implement a monitoring system that flags any new EDC listings published in the EU Official Journal. Automated alerts can be set up through the ECHA website’s RSS feed.

Longer‑term considerations

The amendment signals a shift toward precautionary regulation. Suppliers that invest now in robust toxicology data and flexible formulation platforms will be better positioned for future EU chemicals legislation, such as the anticipated “Green Deal Chemicals Package” slated for 2028. Additionally, aligning with the United States EPA’s TSCA amendments—particularly the new “Significant New Use” (SNU) reporting thresholds for endocrine disruptors—will streamline compliance for companies operating trans‑atlantic supply chains EPA TSCA overview.

Conclusion

The July 2026 REACH amendment introduces stricter EDC criteria, tighter registration timelines and expanded supply‑chain duties. For chemical suppliers, the immediate priority is to identify at‑risk substances, close data gaps, and revise contractual and documentation practices. While the compliance burden is non‑trivial, proactive adaptation will safeguard market access and reduce the risk of costly enforcement actions.

Key take‑away: Treat the amendment as a catalyst for a broader data‑driven compliance strategy rather than a one‑off hurdle.